200 related articles for article (PubMed ID: 18470908)
21. Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.
Carbognin L; Sperduti I; Nortilli R; Brunelli M; Vicentini C; Pellini F; Pollini GP; Giannarelli D; Tortora G; Bria E
Cancer Treat Rev; 2015 Mar; 41(3):262-70. PubMed ID: 25683304
[TBL] [Abstract][Full Text] [Related]
22. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
24. Primary chemotherapy or hormonotherapy for patients with breast cancer.
Brain EG; Misset JL; Rouëss J
Cancer Treat Rev; 1999 Aug; 25(4):187-97. PubMed ID: 10448127
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
26. Taxanes in the treatment of early breast cancer.
Ring AE; Ellis PA
Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
[TBL] [Abstract][Full Text] [Related]
27. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
28. Advances in adjuvant chemotherapy for breast cancer: the role of taxanes.
Kaklamani VG; Gradishar WJ
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S107-18. PubMed ID: 19795584
[TBL] [Abstract][Full Text] [Related]
29. Assessment of clinical response after two cycles of primary chemotherapy in breast cancer.
Beresford MJ; Stott D; Makris A
Breast Cancer Res Treat; 2008 May; 109(2):337-42. PubMed ID: 17624608
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.
Pierga JY; Bidard FC; Mathiot C; Brain E; Delaloge S; Giachetti S; de Cremoux P; Salmon R; Vincent-Salomon A; Marty M
Clin Cancer Res; 2008 Nov; 14(21):7004-10. PubMed ID: 18980996
[TBL] [Abstract][Full Text] [Related]
31. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
Bruzzi P; Del Mastro L; Sormani MP; Bastholt L; Danova M; Focan C; Fountzilas G; Paul J; Rosso R; Venturini M
J Clin Oncol; 2005 Aug; 23(22):5117-25. PubMed ID: 15955906
[TBL] [Abstract][Full Text] [Related]
32. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer.
Martin M; Mackey J; Vogel C
Breast; 2007 Dec; 16 Suppl 2():S127-31. PubMed ID: 17923408
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer.
Knauer M; Haid A; Schneider Y; Köberle-Wührer R; Lang A; Winder T; Alton R; Jasarevic Z; Säly C; Offner FA; Wenzl E; deVries A
Eur J Surg Oncol; 2009 Aug; 35(8):798-804. PubMed ID: 19013747
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy for operable breast cancer.
Mieog JS; van der Hage JA; van de Velde CJ
Br J Surg; 2007 Oct; 94(10):1189-200. PubMed ID: 17701939
[TBL] [Abstract][Full Text] [Related]
35. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
van Nes JG; Putter H; Julien JP; Tubiana-Hulin M; van de Vijver M; Bogaerts J; de Vos M; van de Velde CJ;
Breast Cancer Res Treat; 2009 May; 115(1):101-13. PubMed ID: 18484198
[TBL] [Abstract][Full Text] [Related]
36. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.
Mathew J; Asgeirsson KS; Cheung KL; Chan S; Dahda A; Robertson JF
Eur J Surg Oncol; 2009 Feb; 35(2):113-22. PubMed ID: 18502088
[TBL] [Abstract][Full Text] [Related]
40. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
